Product Information
QULIPTA 60 MG TABLET is a brand product labeled by AbbVie Inc., priced at $38.4494 per EA under NDC 00074709430. Its NADAC has been published 241 times since Feb 23, 2022.
FDA first approved this application on Sep 28, 2021.
Strength
60 mg/1
Manufacturer
AbbVie Inc.NDC
00074709430
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ATOGEPANTApproval Type
New Drug (NDA)
FDA Application
NDA215206FDA Approved
9/28/2021
On Market Since
9/30/2021
Pharmacological Classes
Price Statistics
The NADAC for QULIPTA 60 MG TABLET has been published 241 times since Feb 23, 2022, and over the history we have for it it has risen 20.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $38.4494 per EA |
|---|---|
| All-time high | $38.4749 (May 13, 2026) |
| All-time low | $31.8342 (Feb 23, 2022) |
| 52-week high | $38.4749 |
| 52-week low | $36.6357 |
| Median price | $34.9615 |
| Average price | $34.9506 |
| Largest weekly change | +5.0% (Jan 11, 2023) |
| Weeks tracked | 241 |
| Tracking since | Feb 23, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Atogepant market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AbbVie Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Atogepant market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcitonin Gene-related Peptide Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of QULIPTA 60 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for QULIPTA 60 MG TABLET, manufactured by AbbVie Inc., is $38.4494 per EA (NDC 00074709430), effective Sep 30, 2026.
How has the price of QULIPTA 60 MG TABLET changed over time?
Over the history we have for it, the NADAC for QULIPTA 60 MG TABLET has risen 20.8%. It has been tracked across 241 weekly CMS publications since Feb 23, 2022.
What are the highest and lowest recorded NADAC prices for QULIPTA 60 MG TABLET?
Since Feb 23, 2022, the NADAC for QULIPTA 60 MG TABLET has ranged from a low of $31.8342 (Feb 23, 2022) to a high of $38.4749 (May 13, 2026), with a median of $34.9615 per EA.
Are there cheaper alternatives to QULIPTA 60 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of QULIPTA 60 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures QULIPTA 60 MG TABLET?
QULIPTA 60 MG TABLET (NDC 00074709430) is labeled by AbbVie Inc., and CMS classifies it as a brand product.